{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Polyethylene&page=8",
    "query": {
      "intervention": "Polyethylene",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 479,
    "total_pages": 48,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Polyethylene&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Polyethylene&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T11:14:14.673Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04472091",
      "title": "Genicular Artery Embolization (GAE) for Osteoarthritic Knee Pain",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Knee Osteoarthritis",
        "Knee Pain Chronic",
        "Knee Pain Swelling",
        "Knee Arthritis",
        "Arterial Occlusion"
      ],
      "interventions": [
        {
          "name": "Genicular artery embolization (GAE)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Andrew Picel",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2025-01-15",
      "completion_date": "2026-11-01",
      "has_results": false,
      "last_update_posted_date": "2025-02-24",
      "last_synced_at": "2026-11-19T11:14:14.673Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04472091"
    },
    {
      "nct_id": "NCT00754091",
      "title": "Evaluate Retention of an Orally Administered Device Using Gamma Scintigraphy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "Polymer based lubricating liquid",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Procter and Gamble",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "MALE",
        "summary": "18 Years to 40 Years · Male only"
      },
      "enrollment_count": 16,
      "start_date": "2008-06",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2019-03-26",
      "last_synced_at": "2026-11-19T11:14:14.673Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00754091"
    },
    {
      "nct_id": "NCT03125226",
      "title": "TracelT Hydrogel in Localizing Bladder Tumors in Patients Undergoing Radiation Therapy for Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bladder Carcinoma"
      ],
      "interventions": [
        {
          "name": "Polyethylene Glycol Hydrogel",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2017-10-05",
      "completion_date": "2020-05-18",
      "has_results": true,
      "last_update_posted_date": "2021-02-25",
      "last_synced_at": "2026-11-19T11:14:14.673Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03125226"
    },
    {
      "nct_id": "NCT07700927",
      "title": "Sola2 AMF Knee System Added to Surgery and Antibiotics in Adults With Knee Implant Infection",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prosthetic Joint Infection of Knee"
      ],
      "interventions": [
        {
          "name": "Intervention 1: Alternating Magnetic Field Treatment",
          "type": "DEVICE"
        },
        {
          "name": "Intervention 2 - Sham Treatment",
          "type": "DEVICE"
        },
        {
          "name": "Debridement, Antibiotics, Implant Retention",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Solenic Medical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2026-10-30",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-11-19T11:14:14.673Z",
      "location_count": 2,
      "location_summary": "New Albany, Ohio • Tulsa, Oklahoma",
      "locations": [
        {
          "city": "New Albany",
          "state": "Ohio"
        },
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07700927"
    },
    {
      "nct_id": "NCT01374971",
      "title": "Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Certolizumab Pegol (CZP)",
          "type": "DRUG"
        },
        {
          "name": "Arthroscopic synovial tissue biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Nathan Wei, MD, FACP, FACR:",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2011-09",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2014-04-08",
      "last_synced_at": "2026-11-19T11:14:14.673Z",
      "location_count": 1,
      "location_summary": "Frederick, Maryland",
      "locations": [
        {
          "city": "Frederick",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01374971"
    },
    {
      "nct_id": "NCT00349752",
      "title": "Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "certolizumab pegol 400 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "UCB Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 174,
      "start_date": "2006-11",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2018-08-09",
      "last_synced_at": "2026-11-19T11:14:14.673Z",
      "location_count": 54,
      "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 51 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00349752"
    },
    {
      "nct_id": "NCT02457546",
      "title": "The EVICEL® Neurosurgery Phase III Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cerebrospinal Fluid Leak"
      ],
      "interventions": [
        {
          "name": "EVICEL Fibrin Sealant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hydrogel sealant",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Ethicon, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 234,
      "start_date": "2015-07-01",
      "completion_date": "2017-10-12",
      "has_results": true,
      "last_update_posted_date": "2019-01-10",
      "last_synced_at": "2026-11-19T11:14:14.673Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Sacramento, California • Jacksonville, Florida + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02457546"
    },
    {
      "nct_id": "NCT06950385",
      "title": "Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Familial Adenomatous Polyposis (FAP)"
      ],
      "interventions": [
        {
          "name": "eRapa (encapsulated rapamycin)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rapamycin Holdings Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 168,
      "start_date": "2025-07-18",
      "completion_date": "2031-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-11-19T11:14:14.673Z",
      "location_count": 18,
      "location_summary": "Arcadia, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Weston",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06950385"
    },
    {
      "nct_id": "NCT03808610",
      "title": "Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Recurrent T Acute Lymphoblastic Leukemia",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Refractory T Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Nelarabine",
          "type": "DRUG"
        },
        {
          "name": "Pegaspargase",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2019-04-03",
      "completion_date": "2026-05-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-11-19T11:14:14.673Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03808610"
    },
    {
      "nct_id": "NCT05080218",
      "title": "COVID-19 VaccinE Response in Rheumatology Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis",
        "Psoriatic Arthritis",
        "Spondylarthritis"
      ],
      "interventions": [
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        },
        {
          "name": "Abatacept",
          "type": "DRUG"
        },
        {
          "name": "Secukinumab",
          "type": "DRUG"
        },
        {
          "name": "Tofacitinib",
          "type": "DRUG"
        },
        {
          "name": "TNF Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Canakinumab Injection",
          "type": "DRUG"
        },
        {
          "name": "Baricitinib",
          "type": "DRUG"
        },
        {
          "name": "Ixekizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jeffrey Curtis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 841,
      "start_date": "2021-11-15",
      "completion_date": "2024-05-28",
      "has_results": false,
      "last_update_posted_date": "2025-05-02",
      "last_synced_at": "2026-11-19T11:14:14.673Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05080218"
    }
  ]
}